Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Ovid Therapeutics Inc.NASDAQ: OVID
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $858K fell 62.9% year over year, behind the -26.4% change in trailing-twelve-month other income / expenses. Sequentially, it fell 96.1% from the prior quarter. Over 3 fiscal years it compounded at +162.8% a year.
Context
- Other income / expenses amounted to 345.1% of revenue in FY2025, down 5918.5 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -62.9% toward the trailing-twelve-month pace of -26.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 25.03M USD
- Year-over-year change
- -29.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.03M | -29.4% |
| FY2024 | 2024-12-31 | 35.45M | +410.7% |
| FY2023 | 2023-12-31 | 6.94M | +403.4% |
| FY2022 | 2022-12-31 | 1.38M | +3118.5% |
| FY2021 | 2021-12-31 | (45.69K) | — |
Other Income / Expenses vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 other income / expenses of $23.57M is the 2nd highest of the 11 companies compared; the peer median is $10.59M.
- Its year-over-year change of -26.4% is the 7th highest of 11, against a peer median of +2.9%.
- Other income / expenses amounts to 330.9% of revenue for OVID, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158.99M | +525.4% | +142.9% | 1093.5% | |
| LTM Mar 2026 | $23.57M | -26.4% | +162.8% | 330.9% | |
| LTM Mar 2026 | $14.2M | +6.7% | +60.9% | 44.3% | |
| LTM Mar 2026 | $13.29M | -1.0% | +91.1% | 18.5% | |
| LTM Mar 2026 | $12.12M | +36.6% | +113.1% | — | |
| LTM Mar 2026 | $10.91M | -38.7% | +40.3% | 29.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $10.28M | +47.5% | +96.1% | — |
| LTM Mar 2026 | $6.49M | -46.8% | +29.6% | — | |
| LTM Jun 2026 | $3.53M | +174.6% | — | 64.3% | |
| LTM Mar 2026 | -$15.34M | -85.0% | — | 19.2% | |
| LTM Mar 2026 | -$43.77M | -30.4% | — | 6.5% | |
| Peer median (excluding OVID) | $10.59M | +2.9% | +91.1% | 29.9% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| Weighted Avg Shares | 67.48M | 70.43M | 70.58M | 70.91M | 73.74M |
| Weighted Avg Shares (Diluted) | 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.